FindTrial
Sign In

Phase III Study of ATL-962 in Obese Patients

Phase III Study of ATL-962 in Obese Patients

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221428
Enrollment
Unknown
Registered
2011-04-08
Start date
2011-04-08
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Interventions

investigational material(s) Generic name etc : ATL-962 INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigatio

Sponsors

Takeda Pharmaceutical Company Limited
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inpatient/outpatient during the run-in period: Outpatient The subject can read and understand the written information/consent form and can give his/her consent to participate in this study.

Exclusion criteria

Exclusion criteria: The subject has a serious heart disease, a cerebrovascular disease or a serious disease of the pancreas or blood. The subject has been determined to be ineligible by the investigator or subinvestigator.

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026